Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Episode 26 December 07, 2022 00:39:02
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.
Few & Far Between: How Biotech Gets Built
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Dec 07 2022 | 00:39:02

/

Show Notes

"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can think creatively about the challenges of the cell therapy space." - Chris Min, Longeveron

Biorasi welcomes Chris Min to the Few & Far Between podcast for an inside look at the cell therapy industry and the importance of finding the right team to support your clinical trials. 

Other Episodes

Episode 63

October 28, 2025 01:01:16
Episode Cover

Video Episode 63 - Bruce Leuchter, MD, President and CEO of Neurvati Neurosciences

What if the future of biotech is actually late-stage execution? Welcome to our first video episode of the Biorasi Few & Far Between podcast...

Listen

Episode 35

November 14, 2023 00:44:55
Episode Cover

Episode 35: Charlene Son Rigby, CEO at Global Genes

"And what I was really surprised about was that everybody was doing data collection in a different way. And I kept thinking that, gosh,...

Listen

Episode 38

February 22, 2024 00:38:27
Episode Cover

Episode 38: Dr. Ole Isacson, Professor of Neurology and Neuroscience, Harvard Medical School

"Artificial Intelligence is a tool that really levels up and creates almost like an equity for everybody to participate and, when used effectively, to...

Listen